Wyeth and Curis Link Up in $170 MM Deal to Treat Neurological Disorders

January 2004
Chemical Market Reporter;1/19/2004, Vol. 265 Issue 3, p3
Trade Publication
Reports on the access to Wyeth Pharmaceuticals Inc. to biological signaling pathway technologies developed by Curis Inc. in the U.S. Development of treatment for neurological disorders; Facilitation of preclinical work validating the activity of the small-molecule Hedgehog nerve stimulants; Retention of the licensing rights of Curis.


Related Articles

  • Wyeth Cancels Hedgehog Collaboration with Curis. Turner, Tiffany // BioWorld Today;3/11/2008, Vol. 19 Issue 48, p2 

    This article reports on the decision by Wyeth Pharmaceuticals to terminate its collaboration agreement with Curis Inc. in the U.S. in 2008. The agreement focused on the preclinical development of small-molecule and protein Hedgehog agonists for stroke and cardiovascular indications. Shares of...

  • pharmaceuticals & fine chemicals.  // Chemical Week;7/14/2004, Vol. 166 Issue 23, p24 

    Presents news briefs on issues and events concerning the pharmaceutical and fine chemical industry in Europe as of July 14, 2004. Authorization received by the Therapeutic Antibody Centre of Oxford University from the Medicines and Healthcare Products Regulatory Agency in London, England;...

  • NEWS IN BRIEF. Tyler, Alan // European Chemical News;4/12/2004, Vol. 80 Issue 2095, p26 

    Presents an update on several business enterprises in the petrochemicals industry in Europe as of April 2004. Developments in the collaboration between Avantium Technologies and Degussa; Acquisition of the biocides business of Avecia by Arch Chemicals; Agreement between Solvay Pharmaceuticals...

  • Supply chain. Burridge, Elaine // ICIS Chemical Business;1/29/2007, Vol. 2 Issue 51, p27 

    The article offers world news briefs on the chemical industry supply chain. Honeywell has chosen TRI-K Industries to distribute its Asensa range of personal care products in the U.S., Canada and Mexico. DHL will coordinate the distribution of global clinical trial materials for Wyeth...

  • News Watch.  // Chemical Market Reporter;10/17/2005, Vol. 268 Issue 13, p7 

    Reports global developments in the chemical industry. Joint venture between Wacker-Chemie GmbH and Dymatic Chemicals company; Announcement from Wyeth Pharmaceuticals company that it is phasing out its operation in Rouses Point, New York, a major production site for Premarin; Agreement signed...

  • breaking news Roundup.  // Chemical Market Reporter;9/20/2004, Vol. 266 Issue 9, p3 

    Reports on developments relating to the chemical industry in the U.S. as of September 2004. West Chemical Corp.'s plans in starting its vinyl chloride monomer and polyvinyl chloride operations at its plant in Geismar, Louisiana; Mg Technologies' suspension of Dynamit Nobel Kunststoff GmbH to...

  • Wyeth resumes delivery of Enbrel. Levy, Sandra // Drug Topics;8/5/2002, Vol. 146 Issue 15, p22 

    Reports the decision of Wyeth Pharmaceuticals to resume the regular delivery of the drug Enbrel for rheumatoid arthritis. Effect of the interruption of delivery; Discussion on the effectiveness of the drug; Advice to patients on how to be ensured of uninterrupted therapy.

  • Wyeth updates HRT labels.  // Drug Topics;9/16/2002, Vol. 146 Issue 18, p8 

    Reports that Wyeth Pharmaceuticals has revised the package inserts for its drugs Prempro, Premphase and Premarin. Reflection of safety information from the Women's Health Initiative (WHI) study; Consideration of alternative treatments when using the drugs for the prevention of postmenopausal...

  • NEW DOSING.  // Drug Topics;6/2/2003, Vol. 147 Issue 11, p77 

    Reports on the dosing regimen for Zosyn from Wyeth Pharmaceuticals in the U.S. Approval given by the Food and Drug Administration; Changes in the indication.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics